Stockscreener 앱 받기
23.48
0.36%
-0.082
전일 마감가:
$23.56
열려 있는:
$23.57
하루 거래량:
345.10K
Relative Volume:
0.17
시가총액:
$3.97B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
130.43
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-2.23%
1개월 성능:
+6.61%
6개월 성능:
+6.80%
1년 성능:
+43.40%
1일 변동 폭
$23.10
$23.82
1주일 범위
$22.81
$24.07
52주 변동 폭
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.48 | 3.99B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.94 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.46 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.40 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.84 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study - BMC Neurology
How ACADIA Pharmaceuticals Inc. stock trades before earningsInsider Buying & Real-Time Market Trend Scan - newser.com
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - BioSpace
Is ACADIA Pharmaceuticals Inc. stock oversold or undervalued2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 - openPR.com
Will ACADIA Pharmaceuticals Inc. stock split again soonShare Buyback & Verified Entry Point Detection - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Will ACADIA Pharmaceuticals Inc. stock attract more institutional investorsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
ACADIA Pharmaceuticals (ACAD): JP Morgan Lowers Price Target to $31.00 | ACAD Stock News - GuruFocus
Acadia Eyes Record-Breaking Revenue In 2025 With Nuplazid And Daybue - RTTNews
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights - MSN
(ACAD) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - Yahoo Finance
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - sharewise.com
Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals! - TipRanks
Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com - Investing.com Australia
Insider Sell: James Daly Sells 30,000 Shares of ACADIA Pharmaceu - GuruFocus
Acadia Pharmaceuticals director Daly sells $670k in stock - Investing.com
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersEarnings Summary Report & Daily Stock Momentum Reports - newser.com
Acadia Pharmaceuticals stock price target lowered by RBC on weak Medicaid volume - Investing.com Australia
What drives ACADIA Pharmaceuticals Inc stock priceVolatility Trading Techniques & Free Explosive Earning Power - earlytimes.in
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
자본화:
|
볼륨(24시간):